

# INDEX

(January-December 1963)

## A

- Abscess**  
 in actinomycosis, *Sept.*, 27, 28  
 in blastomycosis, *Sept.*, 13  
 brain, in nocardiosis, *Sept.*, 30  
 extradural, CSF examination, *Aug.*, 15  
 in phycromycosis, *Sept.*, 39, 40  
 subdiaphragmatic, after gastrectomy, *Feb.*, 6
- Acetazolamide**: hepatic coma from, *May*, 5
- Acetophenetidin**: causing hemolytic anemia, *Oct.*, 30, 32
- Acetylsalicylic acid**  
 for pain, *June*, 15, 29  
 side reactions, *June*, 15
- Acidosis**, renal tubular, *Nov.*, 27, 53
- Actinomycosis**, *Sept.*, 26 ff.
- Adrenal gland**  
 cortical hyperfunction, *Mar.*, 6, 12  
 osteoporosis with, *April*, 7, 25  
 cortical insufficiency, and analgesic response, *June*, 21  
 histoplasmosis involving, *Sept.*, 19  
 medulla, tests for tumor, *Mar.*, 17 f.
- Adrenalectomy**: in hypertension, *Mar.*, 46
- Aerosols**  
 to aid expectoration, *Dec.*, 35  
 in bronchitis medication, *Dec.*, 38
- Agranulocytosis**, *Oct.*, 7 ff.  
 clinical picture, *Oct.*, 8, 10 ff.  
 drugs causing, *Oct.*, 7 ff., 14, 47  
 idiopathic, *Oct.*, 14  
 treatment, *Oct.*, 16
- Air pollution**: and chronic bronchitis, *Dec.*, 18 f.
- Airways obstruction**  
 in asthma, *Dec.*, 21  
 in chronic bronchitis, *Dec.*, 6, 8 f., 21  
 generalized  
 diagnosis, *Dec.*, 27  
 management, *Dec.*, 38 ff.  
 infection with, *Dec.*, 23, 24
- Albumin**, serum: in osteoporosis, *April*, 29
- Alcohol**  
 block, for chronic pain, *June*, 38  
 ingestion, effect on response to analgesics, *June*, 21 f.
- Alcoholics**: susceptibility to hepatotoxins, *May*, 9, 10, 42
- Aldosteronism**: hypertension with, *Mar.*, 9, 13
- Allergy**  
 aspergillosis as, *Sept.*, 35 f.  
 in asthmatic attacks, *Dec.*, 21  
 drug  
 causing hepatic damage, *May*, 8 f.  
 clinical syndrome, *May*, 15  
 and postgastrectomy syndrome, *Feb.*, 29
- Allyl-isopropyl-acetylurea**: causing thrombocytopenic purpura, *Oct.*, 17, 19
- Alpha-methyl dopa**: in hypertension, *Mar.*, 44 f.
- Alphaprodine**: as analgesic, *June*, 12, 13
- Amanita phalloides**: as hepatotoxin, *May*, 7
- Amine oxidase inhibitors**: hepatic disease from, *May*, 12, 16, 20 ff.
- Amines**, secondary and tertiary: in hypertension, *Mar.*, 34
- Amino acid transport**: in cystinuria, *Nov.*, 32 ff.
- p-Aminobenzyl caffeine**: hepatotoxicity, *May*, 40, 41
- Aminophylline**: as bronchodilator, *Dec.*, 38 f.
- Aminopyrine**  
 causing agranulocytosis, *Oct.*, 8 f., 10 f., 12, 14  
 causing hemolytic anemia, *Oct.*, 30
- Ammonia**  
 in blood, precipitating hepatic coma, *May*, 4 f.  
 urinary, in stone formation, *Nov.*, 37

- Ammonium compounds, quaternary: in hypertension, *Mar.*, 33 ff.
- Amphetamine: as analgesic, *June*, 18
- Amphotericin B  
   in aspergillosis, *Sept.*, 37 f.  
   in blastomycosis, *Sept.*, 14  
   in candidiasis, *Sept.*, 43  
   in chromoblastomycosis, *Sept.*, 45  
   in coccidioidomycosis, *Sept.*, 24 f.  
   in cryptococcal meningitis, *Sept.*, 6 f.  
   dosage and routes of administration, *Sept.*, 8 f., 11 f., 45  
   in histoplasmosis, *Sept.*, 21 f.  
   in mycetoma, *Sept.*, 44  
   pharmacology, *Sept.*, 7 f.  
   in phycosporiosis, *Sept.*, 40  
   side effects, *Sept.*, 9 f.  
   in sporotrichosis, *Sept.*, 34  
   by vibrapuncture (tattooing), *Sept.*, 45
- Ampicillin: in chronic bronchitis, *Dec.*, 36, 37
- Anabolic agents  
   C-17 alkylated, hepatotoxicity, *May*, 15, 16, 26, 27 f., 35  
   18-ethyl, 17-ethyl derivatives, *May*, 34 f.  
   oral administration and hepatotoxicity, *May*, 8, 35  
   in postgastrectomy syndrome, *Feb.*, 27
- Analgesics  
   blood dyscrasias from, *Oct.*, 13, 14, 30, 44  
   concept of equivalent effective doses, *June*, 11 f.  
   factors modifying responses, *June*, 20 f.  
   mild agents, *June*, 14 f.  
   in combination, *June*, 16, 29  
   morphine antagonists as, *June*, 14  
   optimal dose, *June*, 25  
   potent agents, *June*, 12 f.  
   in combinations, *June*, 17 f.  
   major side effects, *June*, 13  
   respiratory depression and, *June*, 21  
   principles of therapy, *June*, 29
- Anastomosis, in gastrectomy  
   afferent loop obstruction, *Feb.*, 11 f., 24, 28  
   complications, *Feb.*, 5, 7, 8 f.
- Androgens  
   for aplastic anemia, *Oct.*, 42  
   in osteoporosis, *April*, 27 f., 32
- Anemia  
   in acute renal failure, *Jan.*, 16  
   drug-induced  
     by amphotericin B, *Sept.*, 11  
     aplastic, *Oct.*, 36 ff., 47 f.  
     autoimmune hemolytic, *Oct.*, 32 f.  
     hemolytic, *Oct.*, 23 ff., 47 f.  
     megaloblastic, *Oct.*, 33 ff., 47  
   osteoporosis with, *April*, 7  
   in postgastrectomy syndrome, *Feb.*, 22 f., 26 f.
- Aneurysm, aortic: and cerebral vascular insufficiency, *July*, 9
- Angiotensin: as pressor agent, *Mar.*, 8
- Anileridine: as analgesic, *June*, 12, 14, 31
- Antibacterial drugs  
   blood dyscrasias due to, *Oct.*, 46  
   candidiasis from, *Sept.*, 41 f.  
   in chronic bronchitis, *Dec.*, 33, 35  
   hepatotoxicity, *May*, 8, 35 ff.  
   *see also* specific drugs
- Antibiotics  
   in actinomycosis, *Sept.*, 28 f.  
   in acute renal failure, *Jan.*, 17  
   in cancer chemotherapy, *June*, 36  
   disc test for organism sensitivity, *Aug.*, 37  
   hepatotoxicity, *May*, 35 ff.  
   in infections, *Aug.*, 35 ff.  
   serum assay, *Aug.*, 38  
   specific indications for various agents, *Aug.*, 36  
   in rare systemic mycoses, *Sept.*, 44 f.  
   *see also* specific agents
- Anticholinergic drugs: for postprandial symptoms, *Feb.*, 26
- Anticoagulants  
   in carotid artery surgery, *July*, 27  
   for cerebral vascular insufficiency, *July*, 23 f.
- Anticonvulsant drugs  
   causing anemia, *Oct.*, 33 ff., 44  
   hepatotoxicity, *May*, 12, 16, 22 f.
- Antigen-antibody reaction  
   in diagnosis of infection, *Aug.*, 23 f.  
   in drug-dependent hemolytic anemia, *Oct.*, 32

in drug-induced thrombocytopenia, *Oct.*, 10 f.  
 Antimalarials: causing hemolytic anemia, *Oct.*, 29, 30  
 Anuria  
   reflex, *Jan.*, 20  
   total, *Jan.*, 23, 25  
 Arsenicals  
   agranulocytosis from, *Oct.*, 16  
   jaundice from, *May*, 13, 15, 36, 37 f.  
 Arteries  
   candidiasis involving, *Sept.*, 42  
   extracranial  
     obstructive lesions of, *July*, 17  
     subclavian steal blood-flow phenomenon, *July*, 20 f.  
     surgery for occlusive disease, *July*, 29 f.  
   renal  
     occlusion, *Jan.*, 24 ff.  
     stenosis, causing hypertension, *Mar.*, 14  
   vertebral  
     compression in Valsalva maneuvers, *July*, 14  
     obstructive lesions of, *July*, 17, 18, 20  
     vertebral-basilar, ischemia of, *July*, 11 f.  
   *see also* Carotid artery  
 Arteriography  
   in diagnosis of extracranial lesions, *July*, 17, 21 ff., 26  
   in intracranial vessels, *July*, 21 ff.  
 Arteritis, cerebral, *July*, 8  
 Arthritis, rheumatoid: osteoporosis and, *April*, 9, 25  
 Aspergillosis, *Sept.*, 35 f.  
   treatment, *Sept.*, 37 f.  
 Asthma, *Dec.*, 3  
   airways obstruction in, *Dec.*, 21  
   aspergillosis causing, *Sept.*, 35 f., 37  
   corticosteroids in, *Dec.*, 39  
 Atherosclerosis  
   cerebral, *July*, 9  
     sites of predilection, *July*, 18  
   in evolving stroke, *July*, 15 f.

## B

Bacteremia  
   blood culture in, *Aug.*, 9  
   organisms common in, *Aug.*, 11

Barbiturates  
   analgesic effects, *June*, 19, 30  
   for hypertension, *Mar.*, 39  
   in postoperative patients, *June*, 25  
   tolerance for, in hepatic disease, *May*, 4  
 Benzene: causing aplastic anemia, *Oct.*, 44, 45  
 Berylliosis: calcium disorders in, *Nov.*, 26  
 Bile: vomiting of, after gastrectomy, *Feb.*, 11 f.  
 Bladder: calculi: symptoms, *Nov.*, 11  
 Blastomycosis, North American, *Sept.*, 12 ff.  
   diagnosis, *Sept.*, 14  
   antibodies in, *Aug.*, 25  
   skin tests in, *Aug.*, 30  
   treatment, *Sept.*, 14 ff.  
 Blastomycosis, South American, *Sept.*, 44  
 Bleeding  
   anastomotic, after gastrectomy, *Feb.*, 23  
   gastrointestinal, in acute renal failure, *Jan.*, 17  
   occult, from renal stone, *Nov.*, 51  
   in postgastrectomy ulcers, *Feb.*, 13  
 Blood  
   cell counts, and infection, *Aug.*, 33 f.  
   cultures for microorganisms, *Aug.*, 9 ff.  
     number necessary, *Aug.*, 11  
     principles of specimen collection, *Aug.*, 9 f.  
   flow  
     carotid—measurements, *July*, 28  
     cerebral, *July*, 4 ff.  
     renal, and hypotensive agents, *Mar.*, 27, 33  
     renal, in postgastrectomy syndrome, *Feb.*, 18  
   immunologic studies  
     in diagnosis of infection, *Aug.*, 23 ff.  
     in thrombocytopenia, *Oct.*, 20  
   in renal stone diagnosis, *Nov.*, 51, 52

## Blood—Cont'd

### serum

- C-reactive protein in, *Aug.*, 34
- in viral infections, *Aug.*, 18
- smears vs. cultures, *Aug.*, 11
- sugar, in postgastrectomy syndrome, *Feb.*, 16, 20
- viscosity and blood flow, *July*, 6

### Blood dyscrasias

- and cerebral vascular insufficiency, *July*, 9
- drug-induced, *Oct.*, 3 ff.
- incidence, *Oct.*, 7, 12 f., 36
- mechanisms of production, *Oct.*, 3 f., 11

### Blood pressure

- at brain level, *July*, 5 f.
- drugs lowering, *Mar.*, 22 ff.
- management in cerebral vascular insufficiency, *July*, 30 f.
- measurement
  - in diagnosis, *Mar.*, 15
  - historical development, *Mar.*, 3 ff.
- psychologic factors in changes, *Mar.*, 19
- retinal, in carotid occlusion, *July*, 17 f.

### Blood transfusion

- for anemia of renal failure, *Jan.*, 16
- in aplastic anemia, *Oct.*, 41
- incompatible, and renal failure, *Jan.*, 11 f.

### Blood vessels

- cerebral, murmurs, *July*, 19
- factors affecting caliber, *Mar.*, 10

### Bone

- atrophy, *April*, 4
- calcium, and kidney stone formation, *Nov.*, 25, 54
- composition, in osteoporosis, *April*, 11
- cryptococcal lesions, *Sept.*, 5
- formation
  - radioisotope studies, *April*, 23
  - and resorption, in osteoporosis, *April*, 13 ff.
- fragile, *April*, 7
- neoplastic destruction, and calcium metabolism, *Nov.*, 27

### Bone marrow

- effect of chloramphenicol, *Oct.*, 39

transplantation in aplastic anemia, *Oct.*, 43

### Brain

#### circulation

- collateral—disturbances, *July*, 14
- physiology of, *July*, 4 ff.
- "prophylactic" operations, *July*, 29

*see also* Cerebral vascular insufficiency

infarction, mode of onset, *July*, 10

lesions in fungal disease, *Sept.*, 30, 39, 40, 41

metabolism, *July*, 4

thrombosis of, *July*, 15 f.

transient focal ischemia, *July*, 9

tumor, symptoms, *July*, 15

Bretylium tosylate: pharmacology and action, *Mar.*, 38 f.

Brombenzine: hepatotoxicity, *May*, 7

Bronchiectasis, *Dec.*, 26 f.

aspergillosis with, *Sept.*, 36, 37

### Bronchitis

obliterative, *Dec.*, 46

plastic, *Dec.*, 44 f.

Bronchitis, chronic, *Dec.*, 3 ff.

defined, *Dec.*, 6 ff.

diagnosis, *Dec.*, 25 ff.

etiologic mechanisms, *Dec.*, 24

with generalized airways obstruction, *Dec.*, 6, 8 f., 21, 27, 38

infected, *Dec.*, 7 f., 12, 25 ff., 35

mortality, *Dec.*, 4 f., 18, 46

pathology, *Dec.*, 12 ff.

prognosis, *Dec.*, 46 f.

simple, *Dec.*, 6 f., 12, 25

symptoms, *Dec.*, 11

treatment, *Dec.*, 33 ff.

Bronchodilators: in bronchitis and emphysema, *Dec.*, 38 f., 40

Bronchopneumonia: in blastomycosis, *Sept.*, 13

Brucellosis: diagnosis, *Aug.*, 25, 30

### Bruit

carotid artery, *July*, 19

systolic, in renal artery stenosis, *Mar.*, 14

### C

#### Calcium

- absorption, and fat intake, *April*, 22 f.

ic ane-

, July,

rations,

ular in-

t, July,

, Sept.,

July, 9

acology

y, May,

6, 37

ff.

., 24

obstruc-

27, 38

5 ff., 35

6

itis and

3 f., 40

tomycos-

25, 30

stenosis,

e, April,

balance

in hyperthyroidism, *April*, 25

in immobilized patients, *April*,

26

studies, *April*, 18 ff.

content of foods, *April*, 31

dietary

normal intake, *Nov.*, 27

role in osteoporosis, *April*, 16 f.

in therapy of osteoporosis,

*April*, 28, 31, 32

metabolic processes of, *April*, 12

metabolic disorders, conditions

associated with, *Jan.*, 4, 9 f.;

*Nov.*, 24 ff., 52 f.

oxalate, in kidney stones, *Nov.*,

13, 14 f., 16, 21, 28 ff.

phosphate, in kidney stones, *Nov.*,

13, 15, 17

solubility in urine, substances in-

creasing, *Nov.*, 39 ff., 57 f.

urinary, *see* Hypercalciuria

Calculi, renal, *see* Kidney stones

Calculi, urinary: acute obstruction

from, *Jan.*, 22

Cancer

chemotherapy, *June*, 36

hepatotoxicity, *May*, 8

metastases, osteoporosis in, *April*,

9

pain

causes of, *June*, 33

chemotherapy, *June*, 35 f.

morphine combinations for,

*June*, 18

neurosurgery for, *June*, 37 f.

radiation therapy, *June*, 34 f.

patient-physician relation in,

*June*, 33 f.

Candidiasis, *Sept.*, 40 ff.

acute disseminated, *Sept.*, 43

treatment, *Sept.*, 43

Carbon dioxide inhalation: for cere-

bral vascular disease, *July*,

30

Carbon tetrachloride

hepatotoxicity, *May*, 7, 9 ff.

renal lesions from, *Jan.*, 9

Carbutamide: hepatotoxicity, *May*,

25, 26, 27

Carotid artery

blood flow measurements, *July*, 28

ischemia of, *July*, 11 f.

occlusive lesions, *July*, 17, 18

detection methods, *July*, 17 ff.

surgical therapy, *July*, 24 ff.

tandem lesions, *July*, 27

trauma, causing cerebral vascular

insufficiency, *July*, 9

Carpal tunnel syndrome, *July*, 14

Cat scratch fever: skin test, *Aug.*, 30

Catarrrh, pituitous, *Dec.*, 45

Catecholamine

metabolism, inhibitors of, *Mar.*,

43 ff.

in pheochromocytoma, *Mar.*, 17

Catheterization

in obstructive uropathy, *Jan.*, 29

in urine collection, *Aug.*, 12

Cellulitis: in phycomycosis, *Sept.*,

39

Cerebral vascular insufficiency,

*July*, 3 ff.

clinical forms, *July*, 7 f.

extracranial obstructive lesions in,

*July*, 17 ff., 22

ischemia, *July*, 9 ff.

major causes, *July*, 8 f.

treatment

anticoagulant, *July*, 23 f.

medical, *July*, 30 f.

surgical, *July*, 17, 24 ff.

Cerebrospinal fluid

bacteriologic examination, *Aug.*,

14 ff.

collection of specimen, *Aug.*, 14

in cryptococcal meningitis, *Sept.*,

5

culture, *Aug.*, 16

Chancroid

diagnostic tests for, *Aug.*, 21

Ducrey test in, *Aug.*, 31

Children

analgesics in, *June*, 20

renal calculi in, *Nov.*, 8

Chlorambucil: hepatotoxicity, *May*,

41 f.

Chloramphenicol

blood dyscrasias associated with.

*Oct.*, 14, 22, 30, 37 ff.

cautions in use, *Oct.*, 43 f.

hepatotoxicity, *May*, 36, 37

in infected bronchitis, *Dec.*, 36,

37

for nocardiosis, *Sept.*, 31 f.

Chlorisondamine: in hypertension,

*Mar.*, 34

Chlormerodrin: in renal stone treat-

ment, *Nov.*, 57

- Chloroethylaminouracil: hepatotoxicity, *May*, 42
- Chlorothiazide  
hepatotoxicity, *May*, 5, 40, 41  
in hypertension, *Mar.*, 28 ff., 36 f.
- Chlorpromazine  
causing agranulocytosis, *Oct.*, 9 f., 13  
jaundice, *May*, 14, 15, 17 ff.  
potentiating analgesics, *June*, 17, 30
- Chlorpropamide: hepatotoxicity, *May*, 26, 27
- Chlortetracycline: hepatotoxicity, *May*, 35 f.
- Chromoblastomycosis, *Sept.*, 44 f.
- Cigarette smoking: in chronic bronchitis, *Dec.*, 5, 15 f., 18 ff., 33 f.
- Cinchophen: hepatotoxicity, *May*, 12, 23, 24
- Cirrhosis  
biliary, from chlorpromazine jaundice, *May*, 19 f.  
hepatic, *May*, 5, 12
- Citrate: and calcium solubility in urine, *Nov.*, 40
- Climate: and urinary calculi, *Nov.*, 9
- Coarctation of aorta: and hypertension, *Mar.*, 6, 12, 14, 15
- Coccidioidomycosis, *Sept.*, 23 ff.  
diagnosis, *Sept.*, 24  
antibodies in, *Aug.*, 25; *Sept.*, 24  
skin test in, *Aug.*, 31  
treatment, *Sept.*, 24 f.
- Codeine  
as cough suppressant, *Dec.*, 35  
for pain, *June*, 16, 29 f.
- Colic, renal, *Nov.*, 9 ff.
- Coma, hepatic  
causes of, *May*, 4 f.  
treatment, *May*, 43
- Conjunctivitis, inclusion, *Aug.*, 22
- Cor pulmonale  
compared to emphysema, *Dec.*, 9, 10  
in obstructive lung disease, *Dec.*, 24 f., 32 f., 44  
prognosis, *Dec.*, 47
- Cordotomy: for cancer pain, *June*, 37
- Corticosteroids  
for aplastic anemia, *Oct.*, 42  
in bronchitis, *Dec.*, 39 f.  
in jaundice, *May*, 43  
and osteoporosis, *April*, 7, 25  
pretreatment, with amphotericin B therapy, *Sept.*, 11 f.
- Cough  
in chronic bronchitis, treatment measures, *Dec.*, 34 f., 45  
smoker's, *Dec.*, 15  
syncope, *Dec.*, 45 f.
- Cryptococcosis, *Sept.*, 4 ff.  
amphotericin B therapy, *Sept.*, 6
- Crystalloids  
of kidney stone, *Nov.*, 13 ff.  
relation to protein, *Nov.*, 19 ff.  
urinary, and stone formation, *Nov.*, 21 ff., 52
- Crystals  
calcium oxalate, *Nov.*, 15, 16  
calcium phosphate, *Nov.*, 15, 17  
cystine, *Nov.*, 19, 20  
triple phosphate, *Nov.*, 17, 18  
uric acid, *Nov.*, 18, 19
- Culture media  
for blood, *Aug.*, 10  
for intestinal-tract specimens, *Aug.*, 19  
for puncture fluids, *Aug.*, 20  
for sputum, *Aug.*, 18  
for urine, *Aug.*, 13
- Cushing's syndrome: kidney stone in, *Nov.*, 26
- Cyproheptadine: for vasomotor symptoms, *Feb.*, 27
- Cystine  
clearance value, *Nov.*, 31  
in kidney stones, *Nov.*, 19, 20, 32 f., 55
- Cystinuria  
diagnosis, *Nov.*, 34  
as genetic disorder, *Nov.*, 32 ff.  
treatment, *Nov.*, 55 f.
- Cystoscopy: in renal stone diagnosis, *Nov.*, 50 f.

## D

- Decarboxylase inhibitors: in hypertension, *Mar.*, 44 f.
- Decompression: in obstructive uropathy, *Jan.*, 28 ff.
- Desoxyribonucleic acid: in osteoporosis, *April*, 29
- Dextropropoxyphene: as analgesic, *June*, 15, 16, 30

Diabetes mellitus  
phycomycosis in, *Sept.*, 39 f.  
precipitated by thiazides, *Mar.*,  
29, 30

Diazoxide, *Mar.*, 28  
diabetogenic effect, *Mar.*, 30

Diet  
calcium in, *Nov.*, 27  
after gastrectomy, and weight  
loss, *Feb.*, 21  
in hyperoxaluria, *Nov.*, 55  
in jaundice, *May*, 43  
for postgastrectomy syndrome,  
*Feb.*, 25 f.

Dihydrocodeine: as analgesic, *June*,  
16

Diphenylhydantoin  
causing anemia, *Oct.*, 33 f.  
causing jaundice, *May*, 22 f.

Diphtheria  
Schick test, *Aug.*, 32 f.  
throat swabs in, *Aug.*, 17

Diuresis, osmotic: in acute renal  
failure, *Jan.*, 6, 8

Drugs  
choice of, vs. potential toxicity,  
*Oct.*, 4 f.  
combinations and potentiation,  
*June*, 17 ff.  
for pain, *June*, 11 ff.  
mechanisms of relief, *June*, 6  
species difference in, *June*, 11  
placebo response, *June*, 9 f.  
respiratory stimulants, *Dec.*, 44  
response to, factors modifying,  
*June*, 20 ff.  
tolerance and cross tolerance,  
*June*, 21 f.  
toxic reactions  
to analgesics, *June*, 13, 15  
blood dyscrasias, *Oct.*, 3 ff.  
on liver, *May*, 6 ff., 11 ff., 15 f.  
*see also* specific drugs and condi-  
tions

Dumping syndrome, *see* Postgastrec-  
tomy syndrome

Dyspnea: in chronic bronchitis,  
*Dec.*, 7 f.

## E

Echinococcosis: skin test, *Aug.*, 31

Edema, pulmonary: from fluid over-  
loading, *Jan.*, 5, 8

Electrocardiography: in potassium  
intoxication, *Jan.*, 13 f.

Electrolytes  
balance, in hypertension, *Mar.*,  
8 f.

and water loss causing renal fail-  
ure, *Jan.*, 4, 9

Embolism  
cerebral, during arteriotomy,  
*July*, 26

in cerebral vascular insufficiency,  
*July*, 8, 13

Emetics: to aid expectoration, *Dec.*,  
35

Emotions  
and blood pressure, *Mar.*, 5, 10  
and pain reaction, *June*, 8

Emphysema, *Dec.*, 3 ff.  
centrilobular, *Dec.*, 12 ff., 23

definition, *Dec.*, 8  
diagnostic criteria, *Dec.*, 11, 31

mortality, *Dec.*, 5, 16, 46  
panacinar, *Dec.*, 12 ff., 23 f.

pathogenesis, *Dec.*, 22 ff.  
prognosis, *Dec.*, 46 f.

treatment, *Dec.*, 33 ff.

Endarterectomy, carotid: complica-  
tions, *July*, 26 f.

Endocarditis  
bacterial, blood cultures in, *Aug.*,  
11

candidiasis causing, *Sept.*, 41 ff.

Energizers: causing jaundice, *May*,  
20 f.

Enuresis: in chronic obstructive  
uropathy, *Jan.*, 27

Environment  
in chronic bronchitis, *Dec.*, 14,  
18 ff.

and hypertension, *Mar.*, 10, 19

Enzymes  
G-6-PD, in red cell metabolism,  
*Oct.*, 26

hepatic, functions of, *May*, 3 f.

pancreatic, for postgastrectomy  
syndrome, *Feb.*, 26

renin, *Mar.*, 8  
tests, in infectious diseases, *Aug.*,  
34 f.

Ephedrine: as bronchodilator, *Dec.*,  
38

Epilepsy therapy  
causing megaloblastic anemia,  
*Oct.*, 33 ff.

Epilepsy therapy—*Cont'd*  
 hepatotoxic drugs, *May*, 12, 16, 22 f.  
 Erythrocytes  
 count, and packed cell volume, *Aug.*, 33  
 effect of oxidant drugs on, *Oct.*, 24  
 G-6-PD deficient, *Oct.*, 24, 26 ff.  
 pathways of carbohydrate metabolism, *Oct.*, 26  
 sedimentation rate, in infection, *Aug.*, 34  
 Erythromycin: hepatotoxicity, *May*, 36, 37  
 Estrogens  
 impaired metabolism, and hepatic disease, *May*, 5  
 in osteoporosis, *April*, 14 f., 27 f., 32  
 Ethionine: hepatotoxicity, *May*, 7  
 Ethoheptazine: as analgesic, *June*, 15, 16, 30  
 Ethyl alcohol: analgesic effects, *June*, 19  
 Exchange resins  
 effect on urine protective substances, *Nov.*, 41  
 in potassium intoxication, *Jan.*, 15  
 Exercises: to increase ventilatory capacity, *Dec.*, 40 f.  
 Eye: examination in hypertension, *Mar.*, 14

## F

Face  
 actinomycosis involving, *Sept.*, 26  
 phycomycotic infection, *Sept.*, 39, 40  
 Fat, dietary: and calcium absorption, *April*, 22 f.  
 Feces: laboratory examination, *Aug.*, 19 f.  
 Fistula: postgastrectomy, *Feb.*, 5, 6  
 Fluid balance  
 in acute renal failure, *Jan.*, 12 f.  
 in hypertension, *Mar.*, 8 f.  
 Fluid therapy  
 in potassium intoxication, *Jan.*, 15  
 in renal failure, *Jan.* 6 ff., 10; *Mar.*, 53

Fluids, forced  
 in hypercalciuria, *Nov.*, 55, 57  
 in hyperoxaluria, *Nov.*, 55  
 Fluorapatite: formation in bone, *April*, 29  
 Fluorides: in osteoporosis therapy, *April*, 30  
 Fluoxymestrone: hepatotoxicity, *May*, 30, 32  
 Folic acid: for megaloblastic anemia, *Oct.*, 36  
 Food  
 bolus, in postoperative obstruction, *Feb.*, 9  
 calcium content of, *April*, 31  
 causing distention after gastrectomy, *Feb.*, 21  
 restriction, in postgastrectomy syndrome, *Feb.*, 25  
 Forced expiration time, *Dec.*, 27  
 Forced expiratory volume, *Dec.*, 27  
 Foreign bodies: in urinary stone formation, *Nov.*, 43 f.  
 Fractures: in osteoporosis, *April*, 9, 10, 15 f., 27  
 Fungal infections  
 amphotericin B-sensitive, *Sept.*, 8  
 antibodies in diagnosis, *Aug.*, 25  
 with aplastic anemia, treatment, *Oct.*, 41  
 in bronchitis, *Dec.*, 26  
 systemic, *Sept.*, 3 ff.  
 tuberculous meningeal, CSF findings in, *Aug.*, 15  
 Fungus ball, *Sept.*, 36, 43

## G

Gallstone: differentiated from renal stone, *Nov.*, 50  
 Ganglionic blocking agents  
 in hypertension, *Mar.*, 32 ff.  
 parenteral therapy, *Mar.*, 52  
 side effects, *Mar.*, 35  
 Gases, corrosive: causing bronchitis, *Dec.*, 46  
 Gastrectomy  
 complications, *Feb.*, 5 ff.  
 postprandial symptom complexes, *Feb.*, 5, 10 ff.  
 first use of, *Feb.*, 3  
 prognosis postoperatively, *Feb.*, 29  
 ulcer recurrence after, *Feb.*, 12 ff.



Gastric surgery  
 afferent loop obstruction after,  
*Feb.*, 11 f., 24, 28  
 effect on jejunal physiology, *Feb.*,  
 15 ff., 19  
 postgastrectomy syndrome, *Feb.*,  
 3 ff.  
 Gastritis: after gastrectomy, *Feb.*,  
 29  
 Gastrointestinal tract  
 bleeding, in renal failure, *Jan.*, 17  
 flora of, *Aug.*, 19  
 infections, laboratory diagnosis,  
*Aug.*, 18 ff.  
 phycromycosis of, *Sept.*, 39  
 ulceration, in histoplasmosis,  
*Sept.*, 20  
 Gastrojejunostomy: afferent loop  
 obstruction after, *Feb.*, 11 f.,  
 24, 28  
 Genitourinary system: blastomy-  
 cotic infection, *Sept.*, 13  
 Glomerulonephritis, acute: drugs  
 for, *Mar.*, 41  
 Glucocorticoids: hepatic effect,  
*May*, 25  
 Glucose tolerance: and postopera-  
 tive vasomotor symptoms,  
*Feb.*, 29 f.  
 Glucose-6-phosphate dehydrogenase  
 assay techniques, *Oct.*, 29 ff.  
 deficiency, in drug-induced ane-  
 mia, *Oct.*, 23 ff.

Gold  
 agranulocytosis from, treatment,  
*Oct.*, 16  
 aplastic anemia from, *Oct.*, 44, 45  
 thrombocytopenia from, *Oct.*, 17  
 Gonorrhea: diagnostic tests, *Aug.*,  
 21  
 Gout: uric acid excretion in, *Nov.*,  
 36  
 Granuloma inguinale: diagnostic  
 tests, *Aug.*, 22  
 Griseofulvin, *Sept.*, 45  
 Guanethidine sulfate  
 in hypertension, *Mar.*, 36 ff., 47,  
 51, 53  
 pharmacology, *Mar.*, 35 f.

## H

Heart  
 arrhythmias in potassium intoxi-  
 cation, *Jan.*, 13 f.

Candida infections, *Sept.*, 41 f.  
 failure  
 compared to emphysema, *Dec.*,  
 9 ff.  
 in hypertensive patient, *Mar.*,  
 15, 33, 38, 52  
 in obstructive lung disease,  
*Dec.*, 32 f.  
 in hypertension, *Mar.*, 14, 18  
 output  
 effect on ganglion-blocking  
 agents, *Mar.*, 32 f.  
 and guanethidine therapy,  
*Mar.*, 37 f.  
 and prerenal failure, *Jan.*, 4 f.  
 surgery, endocarditis complicat-  
 ing, *Sept.*, 42

Hematuria  
 causes, *Nov.*, 49  
 with kidney stone, *Nov.*, 9, 11  
 in malignant hypertension, *Mar.*,  
 16

Hemoglobinuria: differentiation,  
*Nov.*, 49

Hemorrhage  
 cerebral  
 differentiated from infarct,  
*July*, 16 f.  
 with endarterectomy, *July*, 26  
 gastrointestinal with aplastic ane-  
 mia, *Oct.*, 42  
 massive, after gastrectomy, *Feb.*,  
 5, 6, 7

Hepatitis  
 trophopathic, *May*, 7 f.  
 viral vs. obstructive and drug-  
 induced jaundice, *May*, 11 f.

Hepatotoxins  
 direct, *May*, 6 f., 9 ff.  
 drugs as, *May*, 11 ff.  
 mechanism, *May*, 8 f.  
 indirect, *May*, 7 f.

Heredity  
 of cystinuria, *Nov.*, 32 ff.  
 and hypertension, *Mar.*, 7 f., 13  
 in primary oxaluria, *Nov.*, 31  
 in urinary calculi, *Nov.*, 8 f.

Herpes  
 progenitalis, diagnostic test, *Aug.*,  
 22  
 simplex, *Aug.*, 16  
 skin test for, *Aug.*, 31  
 Hexamethonium: in hypertension,  
*Mar.*, 34

- Hexaphosphoinositol: in hypercalciuria, *Nov.*, 54
- Histamine test: in pheochromocytoma, *Mar.*, 17
- Histoplasmin: skin sensitivity to, *Aug.*, 31; *Sept.*, 17, 21
- Histoplasmosis, *Sept.*, 17 ff.
- chronic cavity, *Sept.*, 20
- diagnosis, *Sept.*, 18 ff.
- antibodies in, *Aug.*, 25
- skin test, *Aug.*, 31; *Sept.*, 17, 21
- treatment, *Sept.*, 21 ff.
- Hormones
- in cancer therapy, *June*, 36
- gonadal
- and calcium retention of bone, *April*, 13 f.
- in osteoporosis therapy, *April*, 26 f., 32
- natural, hepatic effect of large doses, *May*, 25
- Hydralazine
- action of, *Mar.*, 41
- in hypertension, *Mar.*, 42
- side effects, *Mar.*, 42
- Hydrazines: jaundice from, *May*, 21
- Hydrocortisone
- to control amphotericin B side effects, *Sept.*, 10, 11 f.
- for hepatic coma, *May*, 43
- 2-Hydroxystilbamidine
- in blastomycosis, *Sept.*, 14, 15 f.
- side effects, *Sept.*, 15
- in sporotrichosis, *Sept.*, 34
- Hypercalciuria
- idiopathic, *Nov.*, 28
- and stone formation, *Nov.*, 23 ff.
- treatment, *Nov.*, 54 f.
- Hypercarbia: in chronic bronchitis, *Dec.*, 11
- Hyperglycemia: in postgastrectomy syndrome, *Feb.*, 16, 20, 27 f.
- Hyperoxaluria, primary, *Nov.*, 30 f., 53, 55
- Hyperparathyroidism
- osteoporosis with, *April*, 7, 26
- primary
- diagnostic aids, *Nov.*, 25
- and renal stone formation, *Nov.*, 24 f., 28, 52
- renal failure in, *Jan.*, 4, 9
- Hypersensitivity, drug
- causing hepatic damage, *May*, 8
- in diagnosis of jaundice, *May*, 43
- PAS, *May*, 39, 41
- Hypertension
- in acute renal failure, *Jan.*, 17
- in cerebral vascular insufficiency, *July*, 9
- crisis
- acute—treatment, *Mar.*, 41, 43, 45 f.
- parenteral therapy in, *Mar.*, 50
- reserpine in, *Mar.*, 24, 25
- differential diagnosis, *Mar.*, 12
- historical background, *Mar.*, 3 ff., 21 f.
- history and physical examination, *Mar.*, 12 ff.
- malignant
- desirable blood pressure level in, *Mar.*, 47
- ganglionic blocking drugs in, *Mar.*, 32
- with renal failure, *Mar.*, 52 f.
- patient personality in, *Mar.*, 9 f., 18 f.
- psychophysiologic mechanisms, *Mar.*, 9 f.
- remediable causes of, *Mar.*, 5 ff.
- treatment
- of acute crisis, *Mar.*, 41, 43, 45 f.
- basic approaches to, *Mar.*, 47
- with drug combinations, *Mar.*, 29, 31, 42
- with drugs, *Mar.*, 21 ff., 46 ff.
- physician's support as, *Mar.*, 19 f.
- surgical, *Mar.*, 46
- undesirable effects, *Mar.*, 20 f.
- Hyperthyroidism: osteoporosis with, *April*, 7, 25
- Hyperuricemia: of gout, *Nov.*, 36
- Hyperventilation: effect on blood flow, *July*, 7
- Hypokalemia
- from amphotericin B, *Sept.*, 11
- from thiazides, *Mar.*, 29
- Hyponatremia: in renal failure, *Jan.*, 13
- Hypotension
- postural, *Mar.*, 15
- precipitating cerebral ischemia, *July*, 13
- systemic, *July*, 9
- Hypoxemia
- in chronic bronchitis, *Dec.*, 11
- of respiratory failure, *Dec.*, 42 f.

# I

- Immobilization
  - avoidance, in osteoporosis, *April*, 27
  - and kidney stone formation, *Nov.*, 25 f., 54
  - osteoporosis from, *April*, 9, 26
- Infarction, cerebral, *July*, 16
  - complicating carotid artery surgery, *July*, 27
  - differential diagnosis, *July*, 16 f.
  - in evolving-stroke syndrome, *July*, 15
  - mode of onset, *July*, 10
- Infection
  - in acute renal failure, *Jan.*, 16 f.
  - bronchiolar, in emphysema, *Dec.*, 24
  - in chronic bronchitis, therapy, *Dec.*, 35 ff.
  - diagnostic laboratory tests in, *Aug.*, 3 ff.
  - in kidney stone formation, *Nov.*, 37, 43 f., 56
  - urinary tract
    - with catheter drainage, *Jan.*, 30 f.
    - in chronic obstruction, *Jan.*, 27 f.
    - with kidney stone, *Nov.*, 14
- Insecticides: causing aplastic anemia, *Oct.*, 44, 45
- Insulin treatment: in postprandial hyperglycemia, *Feb.*, 27 f.
- Intestines
  - malabsorption after gastrectomy, *Feb.*, 16 f., 19, 21 f., 29
  - obstruction after gastrectomy, *Feb.*, 5, 8
- Intracranial pressure: normal and increased, *July*, 5 f.
- Intussusception, jejuno gastric (retrograde), *Feb.*, 8 f.
- Iodide therapy
  - in aspergillosis, *Sept.*, 38
  - side effects, *Sept.*, 35
  - in sporotrichosis, *Sept.*, 34 f.
- Iproniazid
  - hepatic damage from, *May*, 9, 12, 15, 16, 20 ff.
  - in hypertension, *Mar.*, 43 f.
- Iron deficiency: after gastrectomy, *Feb.*, 23, 24, 26, 29

- Ischemia, cerebral
  - anticoagulants in, *July*, 23 f.
  - differential diagnosis, *July*, 14 f.
  - mode of onset, *July*, 10
  - symptoms, *July*, 11 f.
  - transient focal, *July*, 9 ff.
  - pathogenesis, *July*, 12 ff.
- Isonicotinic acid hydrazide: hepatotoxicity, *May*, 41
- Isoproterenol: for relief of airways obstruction, *Dec.*, 38

# J

- Jaundice
  - canalicular, *May*, 13, 14 f.
  - drug-induced
    - diagnosis, *May*, 42 f.
    - prognosis, *May*, 14, 19
    - treatment, *May*, 43 f.
    - types of, *May*, 11 ff., 14 f.
  - hepatocanalicular, *May*, 13, 14 f.
  - hepatocellular, *May*, 12, 14 f.
  - from direct hepatotoxin, *May*, 10
  - in infections, *Aug.*, 35
  - obstructive vs. drug-induced, *May*, 11 f., 19
- Jejunum: physiologic effects of gastrectomy on, *Feb.*, 15 ff., 19

# K

- Kidney
  - calcification in, *Nov.*, 45 f.
  - cryptococcal infection, *Sept.*, 5
  - damage
    - from candidiasis, *Sept.*, 41, 42
    - from stone, *Nov.*, 11, 43
    - from thiazides, *Mar.*, 29 f.
  - decapsulation, in acute failure, *Jan.*, 11
  - disease
    - acute tubular necrosis, *Jan.*, 6 f., 11 ff., 24
    - analgesic effects in, *June*, 21
    - polycystic, *Jan.*, 9, 28
    - and vascular disease, *Mar.*, 4
  - failure, *see* Renal failure
  - function
    - in amphotericin B therapy, *Sept.*, 9 f.
    - and ganglionic blocking agents, *Mar.*, 34
    - in hypertensive disease, *Mar.*, 16 f., 51

**Kidney—Cont'd**

- outflow tract
  - acute occlusion, *Jan.*, 19, 20 ff.
  - chronic obstruction, *Jan.*, 19 f.
- ptosis, *Jan.*, 20
- stones, *Nov.*, 5 ff.
  - ammonium-containing, *Nov.*, 37, 56 f.
  - calcium, *Nov.*, 23 ff., 54 f.
  - composition and structure, *Nov.*, 12 ff.
  - concretionary, *Nov.*, 21 ff.
  - cystine, *Nov.*, 32 f., 55 f.
  - in hyperparathyroidism, *Jan.*, 9
  - incidence, *Nov.*, 6 ff.
  - initiating lesions, *Nov.*, 44 ff.
  - intrarenal, *Nov.*, 45 f.
  - medical treatment, *Nov.*, 54 ff.
  - mode of formation, *Nov.*, 21 f., 41
  - oxalate, *Nov.*, 28 ff., 55
  - prevention, *Nov.*, 5 f.
  - prognosis, *Nov.*, 58 ff.
  - sedimentary, *Nov.*, 21 ff.
  - surgical treatment, *Nov.*, 53 f.
  - symptoms and signs, *Nov.*, 9 ff.
  - uric acid, *Nov.*, 34 ff., 56
  - xanthine, *Nov.*, 38
- vascular occlusion, *Jan.*, 24 f.

**L**

**Laboratory diagnosis**

- in drug-induced jaundice, *May*, 11 f., 14, 44
- in hypertensive disease, *Mar.*, 15
- in infections, *Aug.*, 3 ff.
  - classification of tests, *Aug.*, 8
  - drug selection and, *Aug.*, 6, 35
  - follow-up examinations, *Aug.*, 8 f.
  - nonspecific clinical tests, *Aug.*, 33 ff.
- in methyltestosterone jaundice, *May*, 28, 30 f.
- serology, *Aug.*, 21, 23 ff.
- skin tests, *Aug.*, 29 ff.
- specimens
  - blood, *Aug.*, 9 ff.
  - cerebrospinal fluid, *Aug.*, 14 ff.
  - gastrointestinal tract, *Aug.*, 18
  - general rules in collecting, *Aug.*, 6 f.
  - puncture fluids, *Aug.*, 20

- respiratory secretions, *Aug.*, 16
- wound, tissue biopsy, pus, *Aug.*, 21, 22 f.

**Labyrinthine disease: and cerebral ischemia, *July*, 14**

**Lead poisoning: hemolytic anemia in, *Oct.*, 33**

**Leptospirosis: laboratory tests, *Aug.*, 15, 26**

**Leukemia: phycomycosis in, *Sept.*, 39 f.**

**Leukocyte count: in infection, *Aug.*, 34**

**Levallorphan, *June*, 14**

**Liver**

**damage by chemical agents, *May*, 5 ff.**

**classification, *May*, 6**

**clinical features, *May*, 9 ff.**

**diagnosis, *May*, 42 f.**

**direct—criteria for, *May*, 6**

**hypersensitivity causing—criteria for, *May*, 8 f.**

**indirect, *May*, 7 f.**

**mechanisms, *May*, 21, 22, 34, 35**

**prevention, *May*, 43 f.**

**treatment, *May*, 43 f.**

**disease**

**analgesic effects in, *June*, 21**

**drug-induced necrosis, *May*, 21, 22, 23**

**hepatocellular, hepatocanalicular and canalicular, *May*, 11**

**effects on exogenous chemicals, *May*, 4**

**function of, *May*, 3 f.**

**in histoplasmosis, *Sept.*, 19**

**with X-5079C therapy, *Sept.*, 16**

**peliosis, *May*, 28**

**Lobotomy, prefrontal: for cancer pain, *June*, 37**

**Lungs**

**actinomycosis of, *Sept.*, 27**

**aspergillosis of, *Sept.*, 36 f.**

**blastomycosis of, *Sept.*, 13**

**cavitation, in fungal infection, *Sept.*, 5, 20, 24, 36**

**chronic disease, *Dec.*, 3 ff.**

**obstructive—epidemiology, *Dec.*, 14 ff.**

**coccidioidomycosis of, *Sept.*, 24**

**cryptococcal infection, *Sept.*, 4 f.**

function tests, in emphysema and congestive failure, *Dec.*, 9, 10  
 histoplasmosis of, *Sept.*, 19, 20  
 nocardiosis of, *Sept.*, 30  
 sporotrichosis of, *Sept.*, 33  
 Lymphadenopathy: in blastomycosis, *Sept.*, 13, 14  
 Lymphatic system and renal stone formation, *Nov.*, 46 f.  
 sporotrichosis involving, *Sept.*, 32  
 Lymphoma: phycormycosis in, *Sept.*, 39 f.  
 Lymphopathia venereum diagnostic tests, *Aug.*, 21, 26  
 Frei test, *Aug.*, 31

## M

M and B 938: hepatotoxicity, *May*, 42  
 Magnesium ammonium phosphate, in kidney stones, *Nov.*, 13, 14, 15 ff.  
 and calcium solubility in urine, *Nov.*, 40, 41  
 Malnutrition after gastrectomy, *Feb.*, 20 ff.  
 osteoporosis in, *April*, 7  
 Mannitol infusion: in renal failure, *Jan.*, 6 f.  
 Mebutamate, *Mar.*, 39  
 Mecamylamine in hypertension, *Mar.*, 34, 37 f., 47, 51  
 in malignant hypertension, *Mar.*, 53  
 Meniere's syndrome: differentiated from cerebral ischemia, *July*, 14  
 Meningitis cerebrospinal fluid findings in, *Aug.*, 14 ff.  
 coccidioidal, amphotericin B in, *Sept.*, 12  
 in coccidioidomycosis, *Sept.*, 24, 26  
 cryptococcal, *Sept.*, 4, 5  
 therapy, *Sept.*, 6 ff.  
 Meningoencephalitis, viral: CSF findings, *Aug.*, 15  
 Meperidine as analgesic, *June*, 12, 13  
 with promethazine, *June*, 17

6-Mercaptopurine: jaundice from, *May*, 8, 42  
 Mercury: renal lesions from, *Jan.*, 8  
 Metabolism calcium, *April*, 12  
 disorders causing renal failure, *Jan.*, 4, 9 f.  
 cerebral, *July*, 4  
 inherited faults of, and kidney stones, *Nov.*, 8  
 rate, and response to sedatives, *June*, 21  
 Methaexamide: hepatotoxicity, *May*, 26, 27  
 Metals, heavy: hepatotoxicity, *May*, 7  
 Methadon: as analgesic, *June*, 12, 13  
 Methandrolone: hepatotoxicity, *May*, 30, 31, 32  
 Methimazole: hepatotoxicity, *May*, 25, 26  
 Methionine in cysteine formation, *Nov.*, 32  
 and hepatic coma, *May*, 5  
 Methotrimeprazine: as analgesic, *June*, 17  
 Methyltestosterone: hepatotoxicity, *May*, 8, 27 ff.  
 Microorganisms in chronic bronchitis, *Dec.*, 26  
 common, in bacteremia, *Aug.*, 11  
 identification, *Aug.*, 8 ff.  
 in cerebrospinal fluid, *Aug.*, 14  
 in gastrointestinal secretions, *Aug.*, 18 ff.  
 in genital lesions, *Aug.*, 21 f.  
 in puncture fluids, *Aug.*, 20  
 in respiratory secretions, *Aug.*, 16 ff.  
 serologic tests in, *Aug.*, 23 f.  
 source of specimen, *Aug.*, 6 f.  
 in urine, *Aug.*, 12 ff.  
 in wounds, tissue biopsies, pus, *Aug.*, 22 f.  
 indications for various antimicrobial drugs, *Aug.*, 36  
 Microscopy, polarizing: in kidney stone analysis, *Nov.*, 14, 23  
 Migraine, aura causing cerebral vascular insufficiency, *July*, 9  
 differentiated from cerebral ischemia, *July*, 14

Milk-alkali syndrome, *Nov.*, 28, 54  
 renal failure in, *Jan.*, 4, 9  
 Monoamine oxidase inhibitors: in  
   hypertension, *Mar.*, 43 f.  
 Mononucleosis, infectious  
   antibodies in diagnosis, *Aug.*, 26  
   drug toxicity resembling, *May*, 16,  
   22  
 Morphine  
   with analeptics, for cancer pain,  
     *June*, 18  
   analgesics equivalent to, *June*, 12  
   antagonists  
     as analgesics, *June*, 14  
     and narcotic combinations,  
       *June*, 18  
   for chronic pain, *June*, 31  
   in drug combinations, *June*, 18  
   hypersensitivity in hepatic dis-  
     ease, *May*, 4  
   respiratory depression and, *June*,  
     21  
 Mucormycosis, *see* Phycomycosis  
 Mucous membrane: candidiasis in-  
   volving, *Sept.*, 41  
 Mumps: skin test in, *Aug.*, 31  
 Muscle relaxants: for pain relief,  
   *June*, 19 f.  
 Mushroom genus: as hepatotoxin,  
   *May*, 7  
 Mycetoma, *Sept.*, 44  
 Myeloma, multiple  
   and hypercalciuria, *Nov.*, 27  
   osteoporosis with, *April*, 9

## N

Nalorphine, *June*, 14  
 Narcotics  
   for acute pain, optimal dose,  
     *June*, 25  
   addiction  
     placebo effects in, *June*, 10  
     in terminal disease, *June*, 31,  
       39 f.  
   for chronic pain, *June*, 30 ff.  
     addiction problem, *June*, 31, 39  
   oral vs. parenteral use, *June*, 14  
   as potent analgesics, *June*, 12 ff.  
   tolerance and cross tolerance,  
     *June*, 21 f.  
 Neomycin  
   in hepatotoxic states, *May*, 43  
   in infected bronchitis, *Dec.*, 37

Neoplastic disease: drug therapy  
   causing liver damage, *May*,  
   41 f.  
 Nephrotic syndrome: and renal fail-  
   ure, *Jan.*, 4, 26  
 Nerve block  
   for chronic pain, *June*, 38  
   sympathetic, for cerebral vascular  
     disease, *July*, 30  
 Nerves, peripheral  
   A delta fibers, *June*, 4 f., 7  
   C fibers, *June*, 4 f., 7  
 Nervous system  
   peripheral, in pain conduction,  
     *June*, 4 ff.  
   sympathetic  
     in hypertension, *Mar.*, 9  
     hypotensive drugs acting on,  
       *Mar.*, 22 ff.  
 Neuropsychiatry: hepatotoxic drugs  
   used in, *May*, 16 ff.  
 Nikethamide: as respiratory stimu-  
   lant, *Dec.*, 43  
 Nitrofurans: causing hemolytic ane-  
   mia, *Oct.*, 30  
 Nocardiosis, *Sept.*, 29 ff.  
   treatment, *Sept.*, 31 f.  
 Norethandrolone: hepatotoxicity,  
   *May*, 28 ff.  
 19-Nortestosterone: hepatotoxicity  
   of ethyl derivative, *May*, 34  
 Nutritional disorders: after gastrec-  
   tomy, *Feb.*, 5, 9 ff.  
 Nystatin, *Sept.*, 45

## O

Occupations: and chronic bron-  
   chitis, *Dec.*, 19, 34  
 Oliguria  
   mannitol infusion for, *Jan.*, 6, 9  
   in prerenal failure, *Jan.*, 5  
   prevention, after incompatible  
     blood transfusion, *Jan.*, 12  
 Osteogenesis imperfecta  
   calcium deficiency in, in captive  
     animals, *April*, 16  
   osteoporosis with, *April*, 7  
 Osteomalacia: bone tissue in, *April*,  
   4  
 Osteoporosis, *April*, 3 ff.  
   bone formation and resorption in,  
     *April*, 13 ff.  
   calcium balance studies in, *April*,  
     18 ff.

cushingoid, *April*, 7, 8  
 diagnosis, *April*, 9 ff.  
 diet in, *April*, 31  
 disuse, *April*, 9, 26  
 idiopathic, *April*, 9  
 incidence, *April*, 5 f.  
 kidney stone formation in, *Nov.*,  
   25 f., 54  
 senile, *April*, 9  
 therapeutic measures, *April*, 26  
 Otitis externa: aspergillus causing,  
   *Sept.*, 36, 37  
 Oxalate  
   crystals, *Nov.*, 15, 16  
   excess, in urine, *Nov.*, 30 f.  
   in kidney stones, *Nov.*, 13, 14 f.,  
     16, 21, 28 ff.  
   synthesis of, *Nov.*, 28  
 Oxygen  
   metabolism of brain, *July*, 4, 6  
   therapy, in respiratory failure,  
     *Dec.*, 42, 43 f.

## P

Pain  
   acute  
     incidence and duration of,  
       *June*, 23 f.  
     specific vs. nonspecific therapy,  
       *June*, 22 f.  
   chest, in chronic bronchitis, *Dec.*,  
     11  
   chronic  
     drug therapy of, *June*, 29 ff.  
     effects on patient, *June*, 26 f.  
     nerve blocks in, *June*, 38  
     role of physician in treatment,  
       *June*, 27 f.  
   drug therapy of, *June*, 11 ff.  
   experience  
     components of, *June*, 6  
     individual variations in, *June*,  
       7 f.  
   impulses, transmission of, *June*,  
     4 ff.  
   nerve blocks for, *June*, 38  
   pathways, *June*, 4 f., 7  
   postprandial, after gastrectomy,  
     *Feb.*, 5, 9 ff., 12 f.  
   relief, in osteoporosis, *April*, 27,  
     28  
   of renal calculus, *Nov.*, 9 ff.  
 Pancreatitis: after gastrectomy,  
   *Feb.*, 5, 6, 7

Para-aminosalicylic acid  
   causing hemolytic anemia, *Oct.*,  
     30, 32  
   hepatotoxicity of, *May*, 13, 14,  
     15, 16, 39 f.  
 Paralysis: kidney stone incidence in,  
   *Nov.*, 25, 54  
 Parasitic infection  
   intestinal, diagnosis, *Aug.*, 20  
   laboratory tests, *Aug.*, 11, 26  
 Parathyroid: in calcium reabsorp-  
   tion, *Nov.*, 23  
 Pasteurellosis: antibody tests in,  
   *Aug.*, 26  
 Peliosis hepatis, *May*, 28  
 D-Penicillamine: in cystinuria, *Nov.*,  
   56  
 Penicillin  
   for actinomycosis, *Sept.*, 27 f.  
   in infected chronic bronchitis,  
     *Dec.*, 36, 37  
 Pentolinium: in hypertension, *Mar.*,  
   34  
 Peptic ulcer  
   calcium intake and kidney stones,  
     *Nov.*, 27 f.  
   history and postgastrectomy syn-  
     drome, *Feb.*, 29  
   history of surgery in, *Feb.*, 4  
   recurrence after gastrectomy,  
     *Feb.*, 12 f.  
 Pericarditis: histoplasmosis causing,  
   *Sept.*, 20  
 Phenacetylurea jaundice, *May*, 22  
 Phenformin: effect on liver, *May*,  
   27  
 Phenindione jaundice, *May*, 40, 41  
 Phenobarbital: in hypertension,  
   *Mar.*, 39  
 Phenol block: for chronic pain,  
   *June*, 38  
 Phenothiazines  
   causing agranulocytosis, *Oct.*, 9  
   f., 11, 13, 14  
   jaundice from, *May*, 16, 20  
   with narcotics, *June*, 17 f., 32  
 Phentolamine test: in pheochromo-  
   cytoma, *Mar.*, 17 f.  
 Phenurone: hepatotoxicity, *May*, 15  
 Phenylbutazone  
   blood dyscrasias associated with,  
     *Oct.*, 14, 22, 44, 45  
   hepatotoxicity, *May*, 13, 15, 23,  
     24

- Pheochromocytoma  
diagnostic signs, *Mar.*, 14, 15  
role in hypertension, *Mar.*, 5, 6,  
13  
tests for, *Mar.*, 17 f., 33
- Phosphorus  
dietary, for renal stone preven-  
tion, *Nov.*, 58  
inorganic, hepatotoxicity, *May*, 7
- Phycomycosis, *Sept.*, 38 f.
- Physician  
communication with laboratory,  
*Aug.*, 5 f.  
relation to patient  
in cancer, *June*, 33 f.  
in hypertension, *Mar.*, 18 f.  
role in treatment of chronic pain,  
*June*, 27 f.
- Phytate: for hypercalciuria, *Nov.*,  
54 f., 57
- Placebo  
effect in narcotic addiction, *June*,  
10  
response in pain experiences,  
*June*, 9 f.
- Plasma volume: in postgastrectomy  
syndrome, *Feb.*, 17 f.
- Pleural fluid: laboratory examina-  
tion, *Aug.*, 18, 20
- Pneumonia  
laboratory diagnosis, *Aug.*, 17, 18  
primary atypical, diagnosis, *Aug.*,  
25
- Poliomyelitis: osteoporosis with,  
*April*, 9, 26
- Postgastrectomy syndrome, *Feb.*, 3  
incidence, *Feb.*, 14 f.  
prophylaxis, *Feb.*, 28 ff.  
symptom complex  
within 1 hour after meals,  
*Feb.*, 14 f.  
2-3 hours after meals, *Feb.*, 18  
treatment, *Feb.*, 25 f.  
weight loss and fatigue in, *Feb.*,  
20 f.
- Potassium  
depletion, in renal failure, *Jan.*,  
4, 9  
exchange, effect of thiazides,  
*Mar.*, 27  
intoxication, *Jan.*, 13 ff.  
therapy  
in postgastrectomy syndrome,  
*Feb.*, 27  
in renal failure, *Jan.*, 10, 11
- Prednisolone: for bronchitis, *Dec.*,  
40
- Primaquine: causing anemia, *Oct.*,  
23 ff.
- Probenecid: hepatotoxicity, *May*,  
23, 24
- Prochlorperazine: in malignant hy-  
pertension, *Mar.*, 53
- Promethazine: with meperidine,  
*June*, 17
- Propylthiouracil: hepatotoxicity,  
*May*, 25, 26
- Prostatism: in urinary tract obstruc-  
tion, *Jan.*, 23, 27
- Protein  
catabolism, measures to reduce,  
*Jan.*, 15 f.  
cerebrospinal fluid, in meningit-  
ides, *Aug.*, 15  
C-reactive, in serum, *Aug.*, 34  
dietary, in osteoporosis, *April*, 29,  
32  
role in kidney stone formation,  
*Nov.*, 12, 19 ff., 41 ff.
- Proteinosis: cryptococcal, *Sept.*, 6
- Protoplasmic poisons: hepatic dam-  
age by, *May*, 6 f.
- Protopratin: in hypertensive  
crisis, *Mar.*, 51
- Pus: bacteriologic study of, *Aug.*,  
23
- Pyelonephritis  
causing renal failure, *Jan.*, 4, 10  
chronic, *Jan.*, 9, 10 f.  
role in hypertension, *Mar.*, 9
- Pyridoxine deficiency: and hyperox-  
aluria, *Nov.*, 30, 55
- Pyrophosphate: and calcium solu-  
bility in urine, *Nov.*, 40 f.
- Q
- Quinidine: causing thrombocytope-  
nic purpura, *Oct.*, 17, 19, 22
- Quinine  
causing hemolytic anemia, *Oct.*,  
30, 32  
causing thrombocytopenic pur-  
pura, *Oct.*, 17, 19, 22
- R
- Radiation therapy: for cancer pain,  
*June*, 34 f.



**Rauwolfia alkaloids**  
 in hypertension, *Mar.*, 24 ff.  
 pharmacology, *Mar.*, 23 f.

**Renal failure**  
 acute  
   complications in, *Jan.*, 16 ff.  
   course of, *Jan.*, 12  
   nonobstructive, *Jan.*, 11 ff.  
   postrenal, *Jan.*, 4  
   prerenal—mechanism, *Jan.*, 4  
   reversible, *Jan.*, 6 ff.  
 in carbon tetrachloride intoxication, *May*, 9 f.  
 chronic reversible, *Jan.*, 9 ff.  
 with malignant hypertension, *Mar.*, 52 f.  
 treatable causes, *Jan.*, 3 ff.  
 from vascular obstruction, *Jan.*, 24 ff.

**Reserpine**: for hypertension, *Mar.*, 24 ff., 47

**Respiratory failure**: in chronic bronchitis, *Dec.*, 41 ff.

**Respiratory system**  
 aspergillosis in, *Sept.*, 35 f.  
 chronic diseases, *Dec.*, 3 ff.  
 cryptococcal infection, *Sept.*, 4  
 histoplasmosis route of infection, *Sept.*, 18 f.  
 insufficiency, and analgesics, *June*, 21  
 secretions, bacteriologic examination, *Aug.*, 16 ff.

**Retina**: arterial pressure and carotid occlusion, *July*, 17

**Rheumatoid factor**: antibody tests of, *Aug.*, 26 f.

**Rickettsioses**: antibody tests, *Aug.*, 27

**Ristocetin**: causing thrombocytopenia, *Oct.*, 20

## S

**Salicylates**: for pain, *June*, 15, 29

**Salmonellosis**  
 antibody reaction in, *Aug.*, 27  
 laboratory diagnosis, *Aug.*, 19 f.

**Sarcoidosis**  
 calcium disorders in, *Nov.*, 26, 53  
 causing renal failure, *Jan.*, 4, 9

**Scarlet fever**: Schultz-Charlton reaction, *Aug.*, 33

**Sclerosis, multiple**: differentiated from cerebral ischemia, *July*, 15

**Scurvy**: osteoporosis in, *April*, 7

**Sedatives**  
 with analgesic drugs, *June*, 30, 32  
 in cerebral vascular insufficiency, *July*, 30, 31  
 in hypertension, *Mar.*, 39, 51  
 in postgastrectomy syndrome, *Feb.*, 27

**Silo filler's disease**, *Dec.*, 46

**Sinusitis, chronic**  
 with chronic bronchitis, *Dec.*, 27  
 treatment, *Dec.*, 34 f.

**Skin lesions**  
 in blastomycosis, *Sept.*, 13  
 in candidiasis, *Sept.*, 40, 41  
 in chromoblastomycosis, *Sept.*, 44  
 cryptococcal, *Sept.*, 5  
 in sporotrichosis, *Sept.*, 32 f.

**Skin tests**  
 in diagnosis of infections, *Aug.*, 29 ff.  
 histoplasmin, *Sept.*, 17, 21

**Sodium**  
 bicarbonate, for potassium intoxication, *Jan.*, 15  
 nitroprusside, in hypertensive crisis, *Mar.*, 45 f.  
 restriction, in hypertension, *Mar.*, 28 f.  
 retention, homeostatic mechanism, *Mar.*, 8  
 and water depletion  
   correction, *Jan.*, 10 f.  
   in renal failure, *Jan.*, 9 ff.; *Mar.*, 52

**Spirochetal infections**: blood films in, *Aug.*, 11

**Spleen**: calcification in histoplasmosis, *Sept.*, 19

**Splenectomy**: in aplastic anemia, *Oct.*, 42 f.

**Sporotrichosis**, *Sept.*, 32 ff.  
 treatment, *Sept.*, 33 ff.

**Sputum**  
 in chronic bronchitis, *Dec.*, 21, 25 f.  
 collection and examination, *Aug.*, 17 f., 20  
 in infected bronchitis, *Dec.*, 7  
 in simple bronchitis, *Dec.*, 6

Staphylococcal infections  
 antibody reaction in, *Aug.*, 27  
 respiratory, *Aug.*, 17  
 Stomach  
 "dumping," *Feb.*, 4, 5  
 rate of emptying  
   effect of gastrectomy on, *Feb.*,  
   10 f.  
   and postprandial symptoms,  
   *Feb.*, 15, 19  
 Streptococcal infections  
 antibody reactions, *Aug.*, 27  
 Schultz-Charlton reaction, *Aug.*,  
 33  
 Streptomycin  
 in chronic bronchitis, *Dec.*, 36, 37  
 for nocardiosis, *Sept.*, 31, 32  
 Strontium: in osteoporosis, *April*,  
 28  
 Sulfadiazine: in histoplasmosis,  
*Sept.*, 22 f.  
 Sulfonamides  
 in bronchitis, *Dec.*, 37  
 causing agranulocytosis, *Oct.*, 7,  
 14  
 causing aplastic anemia, *Oct.*, 44  
 causing hemolytic anemia, *Oct.*,  
 30  
 causing thrombocytopenia, *Oct.*,  
 17, 22  
 hepatotoxicity, *May*, 36, 38  
 in histoplasmosis, *Sept.*, 22  
 in mycetoma, *Sept.*, 44  
 in nocardiosis, *Sept.*, 31 f.  
 in South American blastomycosis,  
*Sept.*, 44  
 Sulfones  
 causing hemolytic anemia, *Oct.*,  
 30  
   hepatotoxicity, *May*, 36, 38 f.  
 Sulfonyleurea derivatives: hepato-  
 toxicity, *May*, 25 ff.  
 Sweat chloride: in chronic bron-  
 chitis, *Dec.*, 22  
 Sympathectomy: in hypertension,  
*Mar.*, 46  
 Sympatholytic drugs: in hyperten-  
 sion, *Mar.*, 35 ff.  
 Sympathomimetic drugs: for relief  
 of airways obstruction, *Dec.*,  
 38 f.  
 Syncope  
 cough, *Dec.*, 45 f.  
 differentiation from cerebral  
 ischemia, *July*, 15

Syphilis: diagnostic tests, *Aug.*, 21,  
 28

## T

Testosterone  
 for aplastic anemia, *Oct.*, 42  
 hepatotoxicity, *May*, 27 ff.  
 oxidized in liver, *May*, 3  
 Tetracycline  
 in chronic bronchitis, *Dec.*, 36,  
 37  
 for nocardiosis, *Sept.*, 31, 32  
 Tetraethylammonium chloride: in  
 hypertension, *Mar.*, 33  
 Thiazide drugs  
 available drugs, *Mar.*, 31  
 effects of, *Mar.*, 9  
 in hypertension, *Mar.*, 28 ff., 37,  
 47  
   pharmacology, *Mar.*, 27 f.  
   side effects, *Mar.*, 29 f.  
 Thiazinamium: for relief of airways  
 obstruction, *Dec.*, 39  
 Thiouracil  
 causing agranulocytosis, *Oct.*, 10,  
 14  
   hepatotoxicity, *May*, 25, 26  
 Thiourea derivatives: jaundice  
 from, *May*, 25, 26  
 Throat  
 cultures, *Aug.*, 17  
 swabs, examination, *Aug.*, 16 f.  
 Thrombocytopenic purpura  
 drugs causing, *Mar.*, 29; *Oct.*, 17,  
 22, 47 ff.  
   pathogenesis, *Oct.*, 19 ff.  
   serologic studies, *Oct.*, 20 f.  
   symptoms and signs, *Oct.*, 17 f.  
   treatment, *Oct.*, 23  
 Thrombosis, cerebral, *July*, 15 ff.  
 CSF examination in, *Aug.*, 15  
 differential diagnosis, *July*, 16 f.  
 evolution of, *July*, 15 f.  
 venous, *July*, 8  
 Thyroid ablation: in respiratory  
 failure, *Dec.*, 43  
 Tolbutamide  
 blood dyscrasias from, *Oct.*, 14,  
 22, 44  
   hepatotoxicity, *May*, 26, 27  
 Toxemia of pregnancy: drugs for,  
*Mar.*, 41, 43

Toxoplasmosis  
 serologic tests, *Aug.*, 28  
 skin test, *Aug.*, 32  
 Tranquilizers  
 with analgesics, *June*, 30, 32  
 hepatotoxicity, *May*, 16 ff., 20  
 for hypertension, *Mar.*, 39  
 Triacetyloleandomycin: hepatotox-  
 icity, *May*, 36, 37  
 Triamcinolone: for aplastic anemia,  
*Oct.*, 42  
 Trichinosis: skin test, *Aug.*, 32  
 Trichomonas vaginalis, *Aug.*, 22  
 Trimethaphan camphor sulfonate:  
 in hypertension, *Mar.*, 34, 51  
 Tuberculosis  
 drug therapy causing hepatic  
 damage, *May*, 39, 41  
 laboratory diagnosis, *Aug.*, 15, 20,  
 23  
 tuberculin test, *Aug.*, 32

## U

Urate: serum values, *Nov.*, 34 f.  
 Uremia  
 in chronic obstructive uropathy,  
*Jan.*, 27  
 complicating kidney injury from  
 stone, *Nov.*, 11  
 Ureter  
 calculi, pain of, *Nov.*, 10  
 obstruction, *Jan.*, 24  
 by stone, *Nov.*, 49  
 occlusion, *Jan.*, 19, 20 ff.  
 Ureteritis cystica, *Jan.*, 20  
 Urethane: hepatotoxicity, *May*, 8,  
 42  
 Urethra  
 causes of obstruction, *Jan.*, 19 f.,  
 23  
 stone in, *Nov.*, 11  
 Uric acid  
 crystals, renal obstructions from,  
*Jan.*, 22  
 kidney stones, *Nov.*, 13, 18 f., 34  
 ff., 56  
 reabsorption, with thiazides,  
*Mar.*, 29  
 synthesis of, *Nov.*, 34 f.  
 Urinary tract  
 calculus, *Nov.*, 48 ff.  
 infection, with kidney stone, *Nov.*,  
 11  
*see also specific structures*

Urine  
 alkalization, *Jan.*, 12; *Nov.*, 55  
 calcium excretion rates in osteo-  
 porosis, *April*, 22, 24  
 catalase determination, *Mar.*, 17  
 crystalline forms of calculi sub-  
 stances in, *Nov.*, 15, 16 ff.  
 collection methods, *Aug.*, 12  
 culture, *Aug.*, 13 f.  
 during catheter use, *Jan.*, 30  
 diversion methods, *Jan.*, 31  
 examination  
 bacteriologic, *Aug.*, 12 ff.  
 in hypertensive disease, *Mar.*,  
 15  
 in urinary calculus, *Nov.*, 48 f.,  
 51 f.  
 proteins, and stone formation,  
*Nov.*, 12, 19 ff., 41 ff.  
 salting-in effects in stone forma-  
 tion, *Nov.*, 39  
 stasis, and stone formation, *Nov.*,  
 43 f.  
 substances increasing calcium sol-  
 ubility in, *Nov.*, 39 ff., 57 f.  
 suppression  
 obstruction causing, *Jan.*, 18 ff.  
 in prerenal failure, *Jan.*, 5  
 Urolithiasis  
 epidemic of, *Nov.*, 8  
*see also* Kidney, stones  
 Uropathy, obstructive, *Jan.*, 27 ff.  
 mechanical, *Jan.*, 24  
 in renal failure, *Jan.*, 18 ff.

## V

Vaccines: antibacterial, in bronchi-  
 tis, *Dec.*, 36 f.  
 Vagotomy: and gastrectomy, com-  
 plications with, *Feb.*, 7, 13,  
 30  
 Valley fever, *Sept.*, 23 ff.  
 Vascular system: examination in  
 hypertension, *Mar.*, 14 f.  
 Vasodilators, cerebral, *July*, 30  
 Vasospasm, cerebral, *July*, 13  
 Ventilation  
 artificial, for respiratory failure,  
*Dec.*, 43  
 in emphysema, *Dec.*, 9, 10  
 measurement of impairment,  
*Dec.*, 27 ff.  
 measurements during bronchitis  
 therapy, *Dec.*, 40

Ventilation—*Cont'd*  
 in respiratory failure, *Dec.*, 41 f.  
 Veratrum alkaloids  
 action and effects, *Mar.*, 39 ff.  
 in hypertensive crisis, *Mar.*, 51  
 Virus infections  
 laboratory diagnosis, *Aug.*, 18, 20  
 meningeal  
   CSF findings in, *Aug.*, 15  
   virus isolation in, *Aug.*, 16  
 serologic tests, *Aug.*, 29  
 skin tests, *Aug.*, 31  
 surface lesions, *Aug.*, 23  
 Vital capacity: in ventilatory impairment, *Dec.*, 27 ff.  
 Vitamin B<sub>12</sub>  
 deficiency, treatment, *Feb.*, 27  
 malabsorption after gastrectomy, *Feb.*, 21, 23, 24, 29  
 Vitamin D  
 intoxication  
   calcium disorders in, *Nov.*, 26  
   renal failure due to, *Jan.*, 4, 9  
   in osteoporosis, *April*, 29, 32  
 Vomiting, postprandial: after gastrectomy, *Feb.* 5, 10 ff.

## W

Water depletion: and renal failure, *Jan.*, 4, 9

Weight  
 loss, postgastrectomy, *Feb.*, 20 ff.  
 as measure of fluid replacement, *Jan.*, 13  
 and response to analgesics, *June*, 20 f.  
 Wounds  
 bacteriologic study, *Aug.*, 22  
 dehiscence, postgastrectomy, *Feb.*, 5, 6 f.

## XYZ

X-5079C  
 in blastomycosis, *Sept.*, 14, 16 f.  
 in coccidioidomycosis, *Sept.*, 25  
 in phycomycosis, *Sept.*, 40  
 in sporotrichosis, *Sept.*, 34  
 Xanthine kidney stones, *Nov.*, 38  
 Xanthomatoses: osteoporosis with, *April*, 7  
 X-ray diffraction analysis: of renal stones, *Nov.*, 14  
 X-ray examination  
   chest, in chronic bronchitis, *Dec.*, 26  
   in emphysema diagnosis, *Dec.*, 32  
   for renal calculi, *Nov.*, 49 ff.  
 Zoxazolamine: hepatotoxicity, *May*, 23, 24

20 ff.  
ment,

*June,*

2  
tomy,

16 f.  
., 25

, 38  
with,

renal

*Dec.,*

*ec.,* 32  
f.

*May,*